Akero Therapeutics (AKRO) EBITDA (2018 - 2025)
Akero Therapeutics (AKRO) EBITDA from Mar 31, 2018 to Sep 30, 2025. The TTM Akero Therapeutics (AKRO) EBITDA is -$471M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Akero Therapeutics (AKRO) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +39.51% |
| 3 Years TTM | +57.32% |
| 5 Years TTM | +48.59% |
| All Time TTM | +25.64% |
Annual EBITDA change of Akero Therapeutics (AKRO)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$219M | -23.14% |
| 2024 | -$285M | +65.12% |
| 2023 | -$173M | +50.15% |
| 2022 | -$115M | +14.15% |
| 2021 | -$101M | +25.83% |
| 2020 | -$80M | +83.26% |
| 2019 | -$44M | -46.48% |
| 2018 | -$82M | N/A |
Comparison Akero Therapeutics (AKRO) five years EBITDA CAGR with competitors
Akero Therapeutics (AKRO) five years EBITDA CAGR is 48.59%.